MTOR and renal cell carcinoma: Although we have not yet examined the correlation between activated ERK1/2 and caveolin-1 in RCC, clearly, the ERK1/2 pathway appears to converge on the mTOR pathway in RCC, given that specific inhibitors of EGFR sensitise RCC cell lines to the effects of rapamycin (Costa et al, 2007).